Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects

Model scores of the 29,894 trials active now.

Model score 7% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 7% of the time (318 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-01-19. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: safety tolerabilityascendingulntolerability pharmacokineticsand pharmacodynamics
  Phrases that lowered it: healthyvaccinevaccinationsinglekg
• Sponsor's past trials: 1629 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Blinding: triple (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Sponsor's past termination rate: 8.2% (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 142 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 9.6% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 73.4% (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 550762 (lowers risk) · Drug's FDA history
• Disease area, psychiatry: No (lowers risk) · Disease area
• Responsible party: sponsor (lowers risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers NCT04232345 · started 2020 · scored riskier than 14% of active trials completed
• A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers NCT05512806 · started 2022 · scored riskier than 1% of active trials completed
• To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia NCT04155645 · started 2019 · scored riskier than 38% of active trials completed
• A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects NCT04142424 · started 2019 · scored riskier than 11% of active trials completed
• A Study to Assess the Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers NCT03420092 · started 2018 · scored riskier than 1% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.